Contact
searchSearch
HMP Global
Login

Multiple Myeloma Excellence Forum

Multiple Myeloma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Nisha Joseph, MD
Videos
The Use of Clinical Pathways in the Treatment of Patients With Multiple Myeloma
11/14/2022
Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.
Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.
Nisha Joseph, MD, discusses...
11/14/2022
Journal of Clinical Pathways
Winston Wong, PharmD
Videos
PFS and Depth of Response Associated With Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Multiple Myeloma
08/17/2022
Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...
Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...
Winston Wong, PharmD, discusses...
08/17/2022
Journal of Clinical Pathways
Marcelo Capra, MD
Interview
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma
07/20/2022
Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...
Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...
Marcelo Capra, MD, discusses...
07/20/2022
Journal of Clinical Pathways
Thomas Martin, MD, UCSF
Interview
Isatuximab Plus Carfilzomib and Dexamethasone for Relapsed MM: Results From the IKEMA Trial
03/30/2022
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses results from the IKEMA trial, which explored the addition of isatuximab to carfilzomib and dexamethasone for patients with relapsed MM.
Thomas Martin, MD, discusses...
03/30/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
Videos
All4Cure: Patient Data Aggregate Platform for Collaborative Multiple Myeloma Care
03/05/2021
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO, provides a demonstration of All4Cure, discusses the vision and need for the platform, and describes its ability to improve patient care.
Tony Blau, MD, Founder and CEO,...
03/05/2021
Journal of Clinical Pathways
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
JCP January/February 2025

Current Issue

February 2025
Volume 11
Issue 1
Current Issue
Issue Archive

Special Reports

Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

Hamza Hashmi, MD
Videos
Recent Advancements in Myeloma Treatment Changing the Standard of Care
04/04/2024

Featuring Hamza Hashmi, MD

Featuring Hamza Hashmi, MD
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, shares insights on recent advancements in myeloma treatment and gives a preview of his session on managing myeloma at the 2024 Community Oncology Conference.
Hamza Hashmi, MD, Memorial Sloan...
04/04/2024
Journal of Clinical Pathways
Suzanne Lentszch, MD, PhD
Videos
Strategies for Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
02/13/2024
Suzanne Lentszch, MD, PhD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Suzanne Lentszch, MD, PhD, discusses the management of high-risk, newly diagnosed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
02/13/2024
Lymphoma, Leukemia & Myeloma Network
Nisha Joseph, MD
Videos
The Use of Clinical Pathways in the Treatment of Patients With Multiple Myeloma
11/14/2022
Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.
Nisha Joseph, MD, discusses antibodies in myeloma and the use of clinical pathways in the treatment of patients with multiple myeloma, touching on new, “ever-evolving” therapeutics and recent drug approvals in the multiple myeloma space.
Nisha Joseph, MD, discusses...
11/14/2022
Journal of Clinical Pathways
Winston Wong, PharmD
Videos
PFS and Depth of Response Associated With Isatuximab Plus Carfilzomib and Dexamethasone in Patients With Multiple Myeloma
08/17/2022
Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...
Winston Wong, PharmD, discusses results from the IKEMA trial, a randomized, open-label, multicenter phase 3 study comparing isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed multiple...
Winston Wong, PharmD, discusses...
08/17/2022
Journal of Clinical Pathways
Marcelo Capra, MD
Interview
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Multiple Myeloma
07/20/2022
Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...
Marcelo Capra, MD, discusses results from a study comparing the benefit of progression-free survival associated with isatuximab in combination with carfilzomib and dexamethasone vs carfilzomib and dexamethasone among patients with relapsed...
Marcelo Capra, MD, discusses...
07/20/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use